Role of Extended Release Quetiapine in the Management of Bipolar Disorders

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2010 Apr 3

PMID 20361059

Citations 5

Authors

Rayan K Al Jurdi

Lena A Dixit

Martha Sajatovic

Affiliations

Soon will be listed here.

Abstract

Atypical antipsychotics have become a widely utilized component of the bipolar disorder treatment armamentarium, with approximately 45% of bipolar patients prescribed atypicals. Over the last decade all atypical drugs except for clozapine have received a Food and Drug Administration (FDA) bipolar indication. In October 2008, the FDA approved quetiapine XR monotherapy for the treatment of acute depressive episodes of bipolar disorder and acute manic or mixed episodes in bipolar I disorder based on two placebo-control trials. Quetiapine was also approved as adjunct therapy with lithium and divalproex for the treatment of acute manic or mixed episodes as well as maintenance of bipolar I disorder. In contrast to immediate release quetiapine which may require a twice-daily regimen, the XR formulation is intended for once-daily administration. This drug profile of quetiapine XR will address chemistry, pharmacodynamics, pharmacokinetics, metabolism, safety and tolerability and clinical trials in bipolar disorder.

Citing Articles

A new synthetic ultrasound-assisted method for dibenzoepines.

Jaskowska J, Drabczyk A, Kulaga D, Zareba P, Majka Z, Jodlowski P Heliyon. 2023; 9(7):e18319.

PMID: 37539205 PMC: 10395526. DOI: 10.1016/j.heliyon.2023.e18319.

Worldwide antipsychotic drug search intensities: pharmacoepidemological estimations based on Google Trends data.

Agren R Sci Rep. 2021; 11(1):13136.

PMID: 34162927 PMC: 8222314. DOI: 10.1038/s41598-021-92204-0.

Efficacy and Safety of Quetiapine for Pediatric Bipolar Depression: A Systematic Review of Randomized Clinical Trials.

Srinivas S, Parvataneni T, Makani R, Patel R Cureus. 2020; 12(6):e8407.

PMID: 32637286 PMC: 7331915. DOI: 10.7759/cureus.8407.

Hospital stay in patients admitted for acute bipolar manic episodes prescribed quetiapine immediate or extended release: a retrospective non-interventional cohort study (HOME).

Karamustafalioglu O, Reif A, Atmaca M, Gonzalez D, Moreno-Manzanaro M, Gonzalez M BMC Psychiatry. 2014; 14:246.

PMID: 25174996 PMC: 4159508. DOI: 10.1186/s12888-014-0246-3.

New drugs for bipolar disorder.

Sanches M, Soares J Curr Psychiatry Rep. 2011; 13(6):513-21.

PMID: 21877160 DOI: 10.1007/s11920-011-0231-1.

References

Calabrese J, Keck Jr P, Macfadden W, Minkwitz M, Ketter T, Weisler R . A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005; 162(7):1351-60. DOI: 10.1176/appi.ajp.162.7.1351. View

Jensen N, Rodriguiz R, Caron M, Wetsel W, Rothman R, Roth B . N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology. 2007; 33(10):2303-12. DOI: 10.1038/sj.npp.1301646. View

Sajatovic M, Madhusoodanan S, Fuller M, Aulakh L, Keaton D . Risperidone for bipolar disorders. Expert Rev Neurother. 2005; 5(2):177-87. DOI: 10.1586/14737175.5.2.177. View

Sajatovic M, Valenstein M, Blow F, Ganoczy D, Ignacio R . Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord. 2006; 8(3):232-41. DOI: 10.1111/j.1399-5618.2006.00314.x. View

Moller H, Johnson S, Mateva T, Brecher M, Svensson O, Miller F . Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia. Int Clin Psychopharmacol. 2008; 23(2):95-105. DOI: 10.1097/YIC.0b013e3282f2d42c. View

Bowden C, BRUGGER A, Swann A, Calabrese J, Janicak P, Petty F . Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA. 1994; 271(12):918-24. View

Altschuler E, Kast R . Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression. Med Hypotheses. 2005; 65(1):65-7. DOI: 10.1016/j.mehy.2005.01.036. View

McElroy S, Keck Jr P . Pharmacologic agents for the treatment of acute bipolar mania. Biol Psychiatry. 2000; 48(6):539-57. DOI: 10.1016/s0006-3223(00)00961-6. View

Sajatovic M, Valenstein M, Blow F, Ganoczy D, Ignacio R . Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder. Psychiatr Serv. 2007; 58(6):855-63. DOI: 10.1176/ps.2007.58.6.855. View

10.

Lingam R, Scott J . Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002; 105(3):164-72. DOI: 10.1034/j.1600-0447.2002.1r084.x. View

11.

Goldsmith D, Wagstaff A, Ibbotson T, Perry C . Lamotrigine: a review of its use in bipolar disorder. Drugs. 2003; 63(19):2029-50. DOI: 10.2165/00003495-200363190-00009. View

12.

Thase M, Macfadden W, Weisler R, Chang W, Paulsson B, Khan A . Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006; 26(6):600-9. DOI: 10.1097/01.jcp.0000248603.76231.b7. View

13.

Yatham L, Kennedy S, Schaffer A, Parikh S, Beaulieu S, ODonovan C . Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009; 11(3):225-55. DOI: 10.1111/j.1399-5618.2009.00672.x. View

14.

Dinan T . Lithium in bipolar mood disorder. BMJ. 2002; 324(7344):989-90. PMC: 1122989. DOI: 10.1136/bmj.324.7344.989. View

15.

Tohen M, Baker R, Altshuler L, Zarate C, Suppes T, Ketter T . Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002; 159(6):1011-7. DOI: 10.1176/appi.ajp.159.6.1011. View

16.

Fountoulakis K, Vieta E, Siamouli M, Valenti M, Magiria S, Oral T . Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder. Ann Gen Psychiatry. 2007; 6:27. PMC: 2089060. DOI: 10.1186/1744-859X-6-27. View

17.

Claxton A, Cramer J, Pierce C . A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001; 23(8):1296-310. DOI: 10.1016/s0149-2918(01)80109-0. View

18.

Pope Jr H, McElroy S, Keck Jr P, Hudson J . Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry. 1991; 48(1):62-8. DOI: 10.1001/archpsyc.1991.01810250064008. View

19.

Yatham L, Paulsson B, Mullen J, Vagero A . Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol. 2004; 24(6):599-606. DOI: 10.1097/01.jcp.0000144887.66319.2f. View

20.

Bowden C, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M . A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 2005; 66(1):111-21. DOI: 10.4088/jcp.v66n0116. View